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Ageneralconsensussupportsfundamentalrolesforbothgeneticandenvironmental,mainlymicrobial,factorsinthedevelopment
of autoimmune diseases. One form of autoimmune rheumatic diseases is conﬁned to a group of nonpyogenic conditions
which are usually preceded by or associated with either explicit or occult infections. A previous history of clinical pharyngitis,
gastroenteritis/urethritis, or tick-borne skin manifestation can be obtained from patients with rheumatic fever, reactive arthritis,
or Lyme disease, respectively, whilst, other rheumatic diseases like rheumatoid arthritis (RA), ankylosing spondylitis (AS), and
Crohn’sdisease(CD)areusuallylackingsuchanassociationwithanoticeablemicrobialinfection.Agreatamountofdatasupports
the notion that RA is most likely caused by Proteus asymptomatic urinary tract infections, whilst AS and CD are caused by
subclinical bowel infections with Klebsiella microbes. Molecular mimicry is the main pathogenetic mechanism that can explain
these forms of microbe-disease associations, where the causative microbes can initiate the disease with consequent productions of
antibacterial and crossreactive autoantibodies which have a great impact in the propagation and the development of these diseases.
1.Introduction
The exact triggering factor in most autoimmune diseases
is unknown, yet an infectious cause has long been suggested
to have an important role in the development of autoimmu-
nity. Manyepidemiologic and clinical reports show a prompt
increase in the incidence of several immune-mediated dis-
orders, such as rheumatoid arthritis (RA), inﬂammatory
bowel disease (IBD), and primary biliary cirrhosis in the
Western populations throughout the world. This rapid
rise in the number of autoimmune diseases cannot be
explained solely on the basis of genetic association, but
also through the involvement of exogenous (environmental)
factors predominantly in the form of microbial infections
[1]. In this review, we are discussing the role of microbes
in some immune-mediated rheumatologic disorders, such
as rheumatic fever, Lyme disease, reactive arthritis (ReA),
RA, ankylosing spondylitis (AS), and Crohn’s disease
(CD).
2. Interplayof Geneticand Environmental
FactorsintheDevelopmentofRA,AS,andCD
It is generally agreed that genetics form the main com-
ponents of the aetiologic factors in the development of
autoimmune diseases. For example, more than 95% of
patients with AS possess HLA-B27, a class I major histo-
compatibility complex (MHC) gene, whilst its frequency
among the general population is less than 10% [2, 3]. So far,
this relationship is considered as the most powerful genetic-
disease association holding true for many diﬀerent popula-
tions [4]. Meanwhile, the frequency of HLA-B27 allelotypes
in CD patients without associated arthritis is usually the
same as in the normal population, but it is increased to up
to 60% in those with involvement of the spinal joints [5].
In RA, however, class II MHC gene, HLA-DR4, is the
most strongly linked genetic marker to this disease. The
frequency of this allelotype has been found to be around
70% in RA patients but it is detected in less than 30% of the2 Autoimmune Diseases
general population [6]. A homologous molecular structure,
consisting of a glutamic acid, glutamine, arginine, argi-
nine, alanine, and alanine “EQRRAA” amino acid sequence
(present in some subtypes of HLA-DRβ1 molecules, such as
HLA-DRβ1∗0401 and HLA-DRβ1∗0404, but not in others
such as HLA-DRβ1∗0402) has been described in patients
withRAandwasgiventhenameof“sharedepitope” [7].The
frequency of the “shared epitope” was found to be increased
to more than 90% in patients with RA [8].
The high associations between genetic haplotypes and
these diseases cannot explain the considerably low incidence
of these conditions among the relatives and even twins of
patients with these diseases. For example, the concordance
rate, the chance of the second twin of developing the disease,
in monozygotic twins was found to be 40% in AS [9], 15%
in RA [10], and less than 14% in CD patients [11], which
indicates that other nongenetic environmental, probably
microbial, factors are also involved in the aetiopathogenesis
of these conditions.
3. Evidence for Associated or
PrecedingBacterialInfectionsin
Some Rheumatic Diseases
Extensive evidence supports the role for microbial infec-
tions in the development of various rheumatic diseases.
The infection whether being associated with or preceding
these conditions usually takes either an overt or occult
form. Furthermore, these rheumatic disorders are usually
associated with certain elements of autoimmune features in
theformofelevatedlevelsofautoantibodiestosystematically
distributed or organ-speciﬁc tissues. Certain examples of
these microbe-triggered immune-mediated rheumatic disor-
ders are discussed below.
3.1. Rheumatic Diseases Following Overt Bacterial Infections
3.1.1. Rheumatic Fever and Streptococcal Infections. Rheu-
matic fever is the prototype of postinfectious rheuma-
tologic conditions following upper respiratory tract infec-
tions by group A beta hemolytic streptococcus pyogenes.
This disease is considerably commoner in developing coun-
tries and its incidence may reach up to 50 per 100,000 [12].
Apart from involving the joints with a classical migra-
tory polyarthritis, this condition is also characterized by
other nonmusculoskeletal features which are induced by
pathological lesions involving the heart (rheumatic carditis),
andbrain(Sydenham’schorea)[13].Patientswithrheumatic
fever showing any of these clinical presentations are usually
investigated for the evidence of previous infections by this
microbe.
Apart from increased levels of anti-streptolysin O titres,
serological analysis in these patients will also show elevated
levels of auto-antibodies against the M protein and carbohy-
drate antigens which are crossreactive with the streptococcal
antigens and expressed on the tissues of joints [14], heart
[15], and basal ganglia in brain [16].
In a recent study, it has been found that passive immu-
nizationwithanti-streptococcalexotoxinBmonoclonalanti-
bodies which also bind cardiac endothelial cells have caused
IgG deposition, complement activation, and apoptotic cell
death in the experimental mouse heart valve [17]. In the
same study, it was shown that the binding ability of these
monoclonal antibodies to the endothelial cells was blocked
signiﬁcantly by pretreatment with crossreactive amino acid
peptide sequences taken from N-Acetyl-β-D-glucosamine,
when conjugated with bovine serum albumin (BSA), but not
with BSA alone.
3.1.2. Lyme Disease and Spirochetal Infections. Lyme disease
or borreliosis, the most common vector-borne illness in
the United States, is a multisystemic disorder caused by
infectionswithspirochetemicrobes,Borreliaburgdorferi,and
transmitted via Ixodes (deer) tick bites [18]. In this disease,
diﬀerent clinical stages with their probable explanations
have been recognized [19]. Patients with Lyme disease are
usually presented with or give a past history of localized skin
manifestations in the form of well-characterized cutaneous
rash and itching described as “erythema migrans” with or
without a ﬂu-like illness resulting from the tick bite. After
a considerable period of time, patients with this illness show
disseminated or wide-spread features due to the involvement
of the cardiac, nervous, and musculo-skeletal systems as
the result of infections by the causative microbes and/or
their associated antimicrobial immune responses. The later
phases of this illness, referred to as chronic Lyme disease and
post-Lyme disease syndrome, are characterized by persistent
arthritic and neurological features occurring as the result
of the tissue damages induced by the eﬀects of the cross-
reacting antibodies to spirochetal and self-antigens [20, 21].
3.1.3. Reactive Arthritis and Its Association with Enteropathic
and Uropathogenic Bacterial Infections. Reactive arthritis
(ReA) is included as one component of a group of several
inter-related but phenotypically diﬀerent disorders that
are collectively named as “spondylarthritis” (SpA) which
comprises AS, psoriatic arthritis, undiﬀerentiated SpA, and
IBD consisting of two subsets; CD and ulcerative colitis [22].
It was in the early twentieth century when a link between
infection and the occurrence of a triad of urethritis, con-
junctivitis and arthritis (Reiter’s syndrome) was discovered
[23]. Reiter’s syndrome was later recognized as a form of
ReA which has commonly been associated with explicit pre-
ceding infections by enteropathic microbial agents including
Campylobacter, Salmonella, Shigella and Yersinia, as well as
the uropathogenic, Chlamydia bacteria [24].
In a most recent study from Finland, ReA was identiﬁed
in 21 out of 45 referred patients suspected of having the
disease after an extensive sewage contamination of the water
supply system in the town of Nokia. Enteropathic microbial
agents, including Campylobacter, Yersinia, and Salmonella,
were isolated in 33% of these patients. These ﬁndings
indicate that mere exposures to infections are not enough
and the interplay of genetic and other susceptibility factors
play a role in the disease pathogenesis [25].Autoimmune Diseases 3
The pathogenetic mechanism in this disease can be
explained on the basis that secretory antibodies against these
microbes which are produced in the gut are transferred
into the joint spaces where they bind tissues expressing
crossreactive self-antigens such as HLA-B27 molecules [26,
27].
3.2. Rheumatic Diseases Associated with Occult or Hidden
Bacterial Infections
3.2.1. Evidence of Immunological, Molecular, and Microbio-
logical Link between Proteus and RA. Since the mid 1980s,
extensive eﬀorts including many studies have emphasized a
role of Proteus mirabilis microbes in the aetiopathogenesis of
RA. Brieﬂy, evidence for the role of Proteus in the initiation
and development of RA can be summarized as follows.
(i) Rabbits injected with HLA-DR4-positive lympho-
cytes were found to produce antibodies which will
only bind to P. mirabilis but not 18 other microbes
[28].
(ii) Tissue-typing sera from pregnant women having
anti-HLA-DR4 speciﬁcity were found to bind more
signiﬁcantly to P. mirabilis than to E. coli [29].
(iii) Molecular similarities were found between “ESR-
RAL” amino acid motifs present in the hemolysins
enzyme products of Proteus microbes and “EQR-
RAA” molecular sequences present in HLA-DR4/1
haplotypes [30]. Furthermore, “IRRET” amino acid
motifsexpressedonsurfaceantigensofProteusurease
enzymes were found to be homologous to “LRREI”
molecular sequences present in type XI collagen
ﬁbres (Figure 1)[ 31].
(iv) Signiﬁcantreciprocalbindingsweredetectedbetween
“EQRRAA” synthetic peptides and ESRRAL anti-
sera raised in rabbits, and also between “ESRRAL”
peptides with anti-EQRRAA antibodies from immu-
nized rabbits. Furthermore, anti-ESRRAL peptide
antibodies were found to bind preferably to mouse
ﬁbroblast transfectant cell line expressing HLA-
DRβ1∗0401, containing EQRRAA sequence, but not
to HLA-DRβ0402, lacking EQRRAA sequence [32].
These results clearly indicate that antibodies to the
“shared epitope” have tissue binding activity.
(v) IgG antibodies from patients with RA were found to
have cytotoxic activities against HLA-DR4-peptide-
bearingcellsasshownbyincreasedhaemolysisforthe
sheep red blood cells coated with HLA-DRβ1∗0404
peptides when compared to sera from AS and healthy
control subjects [27].
(vi) Severalindependentgroupshavefoundthatantibod-
ies to P. mirabilis microbes were signiﬁcantly elevated
in patients with RA compared to those with other
diseases or corresponding healthy subjects recruited
from 15 diﬀerent countries throughout the world
(Table 1)[ 33, 34].
(vii) Evidence for the microbiological link between RA
and Proteus microorganisms are mainly based on the
ﬁndings of a group from Scotland, where the isola-
tion rates of P. mirabilis bacteria from urine samples
of patients with RA were found to be twice as high
as that of E. coli [35]. A similar result was previously
reported by our group from England, where Proteus
microbes were isolated more signiﬁcantly in female
(63%) and male (50%) patients with RA than healthy
women (32%) and men (11%) control subjects [36].
Moreover, urine samples from patients with RA were
also shown to contain elevated levels of antibodies to
P. mirabilis [35], and a positive correlation was found
between the levels of these antibodies in sera and
urine samples of RA patients [37]. Further evidence
has come from results of previous studies, where
patients with RA had increased incidence of urinary
tract infections [38, 39].
These immunological, molecular, and microbiological
ﬁndings support the notions that there is a crucial role for
Proteus microorganisms in the initiation and perpetuation
of RA. Furthermore, evidence exists which indicate that
in RA Proteus infections usually occur in subclinical or
asymptomatic forms [40].
3.2.2. Evidence of Immunological, Molecular, and Microbiolog-
ical Link between Klebsiella and AS. The roles of Klebsiella
pneumonia pathogens in the aetiopathogenesis of AS are
mainly based on results of many studies which have been
carried by several independent groups. These results can be
summarized as follows.
(i) Sera from rabbits immunized with lymphocytes
expressing HLA-B27 haplotypes were binding sig-
niﬁcantly to antigenic extracts of Klebsiella but not
to those of other microbes [43]. Anti-HLA-B27
allogeneic human tissue typing sera were found
to bind more preferably to Klebsiella microbes in
comparison to other HLA-speciﬁc antisera [44].
(ii) HLA-B27 monoclonal antibodies were found to bind
Klebsiella, Shigella, and Yersinia enterobacteria indi-
cating the existence of some crossreactive antigens
in these microbes [45]. Other anti-HLA-B27 mon-
oclonal antibodies, however, were found to bind
Klebsiella more preferably than Shigella and Yersinia
microbial antigens [46].
(iii) Molecular similarities, comprising a hexameric ami-
no acid sequence; glutamine, threonine, aspartic
acid, arginine, glutamic acid, and aspartic acid,
“QTDRED,” have been found between Klebsiella ni-
trogenase reductase enzymes and HLA-B27 self-
antigen molecules [47]. A quadrimeric homologous
structure was also found to exist in both Klebsiella
pullulanase pul-D secretion proteins, comprising;
aspartic acid, arginine, aspartic acid, and glutamic
acid, “DRDE” molecules and HLA-B27 haplotype,
comprising aspartic acid, arginine, glutamic acid,
and aspartic acid, “DRED” molecules, as well as4 Autoimmune Diseases
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Figure 1: Schematic representation of the molecular similarities between bacterial, Klebsiella or Proteus, and self-antigens.
a similarity which involves repeated molecular
motifs, consisting of glycine-x-proline (Gly-x-Pro)
amino acid sequences present in both Klebsiella
pullulanase Pul-A secretion proteins and collagen
type I, III, and IV ﬁbres (Figure 1)[ 48].
(iv) AntiserafromimmunizedrabbitswithKlebsiellawere
found to bind equally to B27-positive lymphocytes
whether obtained from AS patients or healthy con-
trols but not to lymphocytes taken from HLA-B27-
negative individuals [49]. This indicates that there
is no immunological discrepancy between surface
antigens of both diseased and normal HLA-B27
molecules when treated with anti-Klebsiella antibod-
ies.
(v) Klebsiella antibodies were signiﬁcantly elevated in the
serum compared to the synovial ﬂuid of AS patients
[50], indicating that these antibodies are produced
in extra-articular regions such as the enteric mucosal
lymphatic system before gaining entry into the joints.
(vi) Extensive immunological studies have been carried
out during the last three decades by diﬀerent inde-
pendent groups throughout the world. The results
of these studies indicate that antibodies against K.
pneumoniae and/or crossreactive self-antigens but
not against other microbial agents are signiﬁcantly
elevated among patients with AS when compared to
patients with other diseases or to healthy individuals
(Table 1)[ 41, 42].
(vii) IgG antibodies from AS patients were found to pos-
sess signiﬁcant in vitro cytotoxic activities to HLA-
B27 peptide-bearing cells when compared to RA
patients or healthy subjects, when they showed
increased percentage lysis of the sheep red blood
cells coated with HLA-B27 peptides containing the
crossreactive antigens [27].
(viii) Antibodies to Klebsiella nitrogenase “QTDRED-”
containing peptides were found to bind the synovial
tissues of AS patients more signiﬁcantly when com-
pared to those from patients with other rheumatic
diseases [51].
(ix) MicrobiologicalevidenceforalinkbetweenKlebsiella
microorganisms and AS are mainly based on the
results of various studies, where increased isolation
rates of Klebsiella from the bowel of AS patients
have been reported to correlate with disease activity
status [52–55]. Other groups, however, could not
ﬁnd such an association [56, 57]. These discrepancies
in the results could be explained by the diﬀerences
in the method of collection and culture of the
faecal specimens and the disease activity status.
Furthermore, in patients with AS elevated levels of
IgA Klebsiella antibodies were found to be associated
with a higher degree of gut inﬂammation [58]a n d
the source of these bacterial antibodies were shown
to be the jejunal region of the gut [59].
(x) HLA-B27 transgenic rats raised in a germ-free envi-
ronment do not develop many features of SpAs,
particularly the gut and arthritic lesions, which
may indicate that the commensal gut ﬂora plays an
important role in the pathogenesis of B27-associated
arthropathies [60].
The results of these studies together with those which
have shown histological signs of inﬂammations [61, 62]a n d
an increase in the gut permeability [63] in patients withAutoimmune Diseases 5
Table 1:Characteristicsofbacterialimmuneresponsesinpatientswithrheumatoidarthritisandankylosingspondylitis(see[33,34,41,42]).
Rheumatoid arthritis (RA) Ankylosing spondylitis (AS)
Disease-triggering bacteria Proteus mirabilis Klebsiella pneumoniae
Bacterial antigens Hemolysin; Urease Nitrogenase; Pullulanase
Self-antigens∗ HLA-DR4/1; collagen XI HLA-B27; collagens I, III and IV
Antibody isotypes IgG IgA and IgG
Source of bacterial infections Upper urinary tract Large bowel
Bacterial isolations P. mirabilis isolated more signiﬁcantly from urine
of active RA patients
K. pneumonia microbes are more abundant in the
large bowel of active AS patients
Evidence for cytotoxic activities Proteus antibodies are cytotoxic to cells coated
with crossreactive self antigens
Klebsiella antibodies are cytotoxic to cells coated
with crossreactive self antigens
Countries∗∗
England; Ireland; Scotland; USA; Canada; France;
Norway; Bermuda; Japan; Taiwan; India;
Netherlands; Spain; Russia and Finland
England; Scotland; USA; Canada; Slovakia; China;
Netherlands; Turkey; Japan; Finland; Sweden;
Mexico; Germany; Taiwan; India; Russia; Spain
Microbial controlsΔ
Klebsiella, Escherichia, Yersinia, Salmonella,
Chlamydia, Shigella, Pseudomonas,
Campylobacters, and viruses
Proteus, Escherichia, Yersinia, Salmonella,
Streptococci, Borrelia, Pseudomonas, Candida, and
Campylobacters
Disease controlsΔΔ AS, systemic lupus erythematosus, sarcoidosis,
acute anterior uveitis, spondyloarthropathy
RA, psoriatic arthritis, osteoarthritis, reactive
arthritis, systemic lupus erythematosus
∗Self-antigens crossreactive with the corresponding bacterial antigens
∗∗CountrieswithrecruitedcohortpatientsshowingelevatedlevelsofantibodiesagainstProteus(inRA),Klebsiella (inAS)aswellasagainstthecorresponding
crossreactive self-antigens
ΔMicrobial agents used as controls but showing no enhanced humoral immune responses in patients with RA or AS
ΔΔDisease controls showing normal immune responses to Proteus (in RA) and Klebsiella (in AS).
AS support the hypothesis that the main bacterial immune
response involves mucosal immunity with signs of overt or
more commonly occult or asymptomatic intestinal infec-
tions by Klebsiella microorganisms.
3.2.3. Evidence of Immunological and Microbiological Link
between Klebsiella and CD. Evidence exists which supports
direct and indirect roles for the environmental factors,
mostly bacterial, and more speciﬁcally involves Klebsiella
microbes in the pathogenesis of CD. These can be summa-
rized as follows.
(i) Identical twins of patients with CD are less prone
to develop the disease [11], indicating the role for
an environmental factor in the development of this
disease.
(ii) Increased incidences of CD have been reported
among closely living friends of CD patients [64]a s
well as among small town populations in Southern
Italy [65]. Furthermore, a slow increase in the
incidence of CD was observed among migrants who
are moving from a low to high risk area [66].
(iii) Pretreatmentofmicewithantibioticshasbeenshown
to alleviate intestinal inﬂammation in experimental
animal models [67, 68], which gives further support
to the involvement of gut bacteria in CD.
(iv) Various independent groups have shown that anti-
bodies to Klebsiella and/or to crossreactive collagen
antigens were elevated more signiﬁcantly in patients
with CD when compared to the control groups [69].
(v) Evidence of the microbiological links of Klebsiella
with CD has been mainly based on the isolation of
these microbes from large bowel specimens in more
than 25% of patients with CD [70]. Moreover, the
disease relapses in patients with CD were found to be
associated with Klebsiella oxytoca colitis [71].
It appears from these data results that unlike rheumatic
fever, Lyme disease, and ReA, infections by Proteus and
Klebsiella microbes in RA and AS/CD, respectively, usually
occur in occult or subclinical forms, and that antibodies
to the causative microbes and crossreactive self-antigens are
detected frequently in active patients with these diseases
when compared to control groups.
4. Exogenous (Microbial)and Endogenous
FactorsArethe Most LikelyCauses
ofAutoantibodyProductionsinRA
It should be emphasized that apart from antibodies against
the self-antigens, HLA-DR4/1, and collagen ﬁbres, most if
not all other autoantibodies such as rheumatoid factor (RF),
anticyclical citrullinated protein/peptide antibodies (anti-
CCP), and antineutrophil cytoplasmic antibodies (ANCA),
which are commonly detected in patients with RA [72,
73], are most likely to be produced as the result of B
cell stimulation by exogenous (microbial) agents and/or the
eﬀect of some endogenous enzymatic factors.
The interrelation between RF and RA could be explained
on the basis of the following ﬁndings: ﬁrstly, RF can also
be detected in increased levels in patients with various viral,
bacterial, and parasitic infections [74]. Secondly, RFs can be6 Autoimmune Diseases
induced in the mice by polyclonal B cell stimulation with
lipopolysaccharides [75]. Thirdly, RFs could be generated
by immunization with collagen II antigen-antibody [76]
and RF-like immune complexes [77] in experimental mice.
Finally, RFs were found to disappear in patients with
subacute bacterial endocarditis when the causative microbes,
Streptococcus, were eradicated by antibiotic therapy [78].
Anti-CCP antibodies, which have been found in early
c a s e so fR A[ 79], can be linked to Proteus infections through
the eﬀects of peptidyl arginine deiminase (PAD) enzyme
on the arginine-containing structures of Proteus hemolysin
and urease antigens and the counterpart crossreactive HLA-
DR4/1 and collagen XI self-antigens, with the production
of citrulline-containing compounds which form the main
antigenic components of citrullinated proteins [34, 80]. The
associationofRFsandanti-CCPantibodieswithRAexplains
the existence of a positive correlation between increased
levels of these antibodies and the presence of HLA-DR4/1
shared epitope [81] as well as the disease activity and severity
in patients with RA [82]. Furthermore, anti-CCP antibodies
have also been reported in patients with various microbial
infections [83].
Unlike other autoantibodies, ANCAs were recognized
in a lower proportion, usually in less than 25% [84,
85] of patients with RA. Apart from RA, however, these
antibodies have also been reported in many other diseases,
including microbial infections, especially when associated
with systemic vasculitis [73]. Moreover, proteinase-3, which
is considered as one of the predominant antigens that
speciﬁcally binds to ANCA, is found to have similarities with
some bacterial antigenic proﬁles [86].
5.MolecularMimicryHypothesisand
PathogeneticMechanismintheDevelopment
of Microbe-TriggeredRheumatic Diseases
Although the avidity of the interactions between antigenic
determinants and speciﬁc antibodies is considerably high,
these antigen-binding sites can allow epitopes of similar
shapesexpressedoncompletelydiﬀerentmicrobialoranimal
cells to bind these antibodies, albeit with a lower binding
avidity. These so-called crossreactive epitopes are made up of
essentially the same amino acid and carbohydrate molecules,
andsuchcrossreactionsareinfactcommonandmayaccount
for the undesirable production of antibodies against self-
molecules which occurs in some autoimmune diseases.
Molecular mimicry or crossreactivity hypothesis pro-
poses that an exogenous substance, mostly produced or
possessed by infectious agents, may trigger an immune
response against self-antigens. According to this theory sus-
ceptible individuals acquire an infection by a microbial
agent that has antigenic similarity to self-antigens. As the
result, these pathogen-speciﬁc antibodies bind to the host
structures possessing crossreactive self-antigens and cause
tissue damage and disease.
Molecular mimicry has been linked to the pathogenesis
ofseveralimportantdiseases,suchasrheumaticheartdisease
[87], multiple sclerosis [88], and type 1 diabetes mellitus
[89]. In rheumatic fever carditis, for example, the basic
pathogenetic process involves production of antibodies
against Streptococcus which express high levels of M protein
antigens, a molecule that shares structural similarities with
thosefoundintheheartvalvesandendocardialmembrane.If
antibodies to these bacterial proteins reach high levels, there
may be suﬃcient binding to the host cells possessing these
cross-reactive antigens with activation of the complement
system and induction of the pathological damages at these
sites.
The mechanism of molecular mimicry, however, can also
be used in the explanation for the development of RA, AS,
and CD after infections by the causative microbes. In AS,
for example, after a preliminary gut mucosal activation by
Klebsiella microbes and production of the secretory anti-
Klebsiella IgA antibodies, recurrent bouts of subclinical Kleb-
siella infections in the large bowel of susceptible individuals
carrying HLA-B27 will lead to production of increased
levels of Klebsiella IgG antibodies. When the level of these
antibodies reaches a certain limit, they will be able to activate
the classical cascade of complement system and destroy
tissuesviatheeﬀectofendproductsofthecomplementcom-
ponents, mainly C8 and C9, “membrane attack complex.”
At the same time, certain activated complement components
such as C3a and C5a help in the propagation of the inﬂam-
matory process through recruitment (chemoattraction) and
activation of the neutrophils and phagocytes with the release
of cytotoxic and destructive enzymes by these cells. Other
chemoattractants, such as leukotriene B4, can be released
by the autoantibody targeted cells. Inﬂammatory cells are
further activated by binding to autoantibody Fc regions and
ﬁxed complement C3 fragments on the tissue cells, thus
causing further tissue injury via eﬀects of the products of
activated inﬂammatory cells.
There is a requirement for the presence of high levels
of anti-Klebsiella IgG antibodies in order that classical
complement cascades will be activated and this will occur
in patients with AS mainly during the active phases of the
disease [90, 91]. The same pathogenetic process can also be
applied to RA being caused by recurrent bouts of Proteus
asymptomatic urinary tract infections.
6. Conclusions
The aetiopathogenetic mechanism which plays a major
role in the causation and development of one group of
autoimmune diseases involves interplay between the genetic
and environmental factors. Microbes form an important
part in the disease causations in most immune-mediated
rheumatic diseases, such as rheumatic fever, ReA, Lyme
disease, RA, AS, and CD. Molecular mimicry is considered
as the basic mechanism which leads to the development of
these diseases, in genetically susceptible individuals, where
the causative microbe triggers formation of antimicrobial
antibodies which could bind the crossreactive self-antigens
and cause tissue damages via the eﬀects of activated com-
plement system and the cytotoxic products from recruited
inﬂammatory cells.Autoimmune Diseases 7
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